title: Erythroleukaemia in the north of England: a population based study.
abstract: OBJECTIVE
  To evaluate the incidence and outcome of acute myeloid leukaemia (AML), FAB M6 (erythroleukaemia).
  
  
  METHODS
  A demographic study in the Northern Health Region of England between 1983 and 1999.
  
  
  RESULTS
  Thirty three cases were diagnosed and registered prospectively. The overall incidence was 0.077 cases/100,000/year. There was a pronounced rise in incidence in patients aged 56 years or more: 6.6 times higher than that in younger patients. Overall survival was poor; median survival was 11 months for those aged less than 56 years, and three months for patients aged 56 years and above (p = 0.045). Acquired karyotypic abnormalities were found in 17 of 27 patients where analysis was attempted. When classified according to the criteria of the Medical Research Council AML trials, karyotype predicted survival, with a median overall survival of 14 months for those with "standard risk" cytogenetic results and two months for "poor risk" results (p = 0.005).
  
  
  CONCLUSIONS
  This study demonstrates a worse survival for patients with erythroleukaemia than that reported in some published trials of selected patients.
authors.affiliation: Department of Haematology, Royal Victoria Infirmary, Newcastle upon Tyne NE1 4LP, UK.
authors.forename: A W
authors.initials: AW
authors.lastname: Wells
authors.forename: N
authors.initials: N
authors.lastname: Bown
authors.forename: M M
authors.initials: MM
authors.lastname: Reid
authors.forename: P J
authors.initials: PJ
authors.lastname: Hamilton
authors.forename: G H
authors.initials: GH
authors.lastname: Jackson
authors.forename: P R
authors.initials: PR
authors.lastname: Taylor
mesh_terms: D000328:Adult; D017677:Age Distribution; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use; D002675:Child, Preschool; D003561:Cytarabine / Q000008:administration & dosage; D003582:Cytogenetics; D003630:Daunorubicin / Q000008:administration & dosage; D004739:England / Q000453:epidemiology; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage; D006801:Humans; D015994:Incidence; D004915:Leukemia, Erythroblastic, Acute / Q000188:drug therapy / Q000453:epidemiology*; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D012306:Risk; D015996:Survival Rate; D013866:Thioguanine / Q000008:administration & dosage; D016896:Treatment Outcome; D014740:Vidarabine / Q000008:administration & dosage / Q000031:analogs & derivatives
chemical_list: D003561:Cytarabine; D016179:Granulocyte Colony-Stimulating Factor; D005047:Etoposide; D014740:Vidarabine; D013866:Thioguanine; D003630:Daunorubicin